113 related articles for article (PubMed ID: 37781631)
1. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA; Long MD; Kosaka Y; Mulkey JS; Coy JL; Agarwal A; Lind EF
bioRxiv; 2023 Sep; ():. PubMed ID: 37781631
[TBL] [Abstract][Full Text] [Related]
2. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA; Long MD; Kosaka Y; Long N; Mulkey JS; Coy JL; Agarwal A; Lind EF
Front Immunol; 2024; 15():1297338. PubMed ID: 38495876
[TBL] [Abstract][Full Text] [Related]
3. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication.
Rickmann M; Krauter J; Stamer K; Heuser M; Salguero G; Mischak-Weissinger E; Ganser A; Stripecke R
Ann Hematol; 2011 Sep; 90(9):1047-58. PubMed ID: 21520003
[TBL] [Abstract][Full Text] [Related]
4. Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses.
Lau CM; Nish SA; Yogev N; Waisman A; Reiner SL; Reizis B
J Exp Med; 2016 Mar; 213(3):415-31. PubMed ID: 26903243
[TBL] [Abstract][Full Text] [Related]
5. Constitutive Flt3 signaling impacts conventional dendritic cell function.
Wilson KR; Macri C; Villadangos JA; Mintern JD
Immunol Cell Biol; 2024 May; ():. PubMed ID: 38693626
[TBL] [Abstract][Full Text] [Related]
6. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
7. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
8. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
[TBL] [Abstract][Full Text] [Related]
9. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of NK cell RIPK1 with Prognosis of Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].
Yu G; Chen JG; Tan JS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1480-1485. PubMed ID: 33067941
[TBL] [Abstract][Full Text] [Related]
11. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
[TBL] [Abstract][Full Text] [Related]
14. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
15. Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia.
Rickmann M; Macke L; Sundarasetty BS; Stamer K; Figueiredo C; Blasczyk R; Heuser M; Krauter J; Ganser A; Stripecke R
Ann Hematol; 2013 Aug; 92(8):1079-90. PubMed ID: 23616009
[TBL] [Abstract][Full Text] [Related]
16. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
[TBL] [Abstract][Full Text] [Related]
17. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
18. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.
He BL; Yang N; Man CH; Ng NK; Cher CY; Leung HC; Kan LL; Cheng BY; Lam SS; Wang ML; Zhang CX; Kwok H; Cheng G; Sharma R; Ma AC; So CW; Kwong YL; Leung AY
EMBO Mol Med; 2020 Apr; 12(4):e10895. PubMed ID: 32134197
[TBL] [Abstract][Full Text] [Related]
19. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
20. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]